Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

Journal:
Nature Medicine
Published:
Affiliations:
20
Authors:
29
Institutions Authors Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
9.333333
0.32
Ludwig Center at Harvard Medical School, United States of America (USA)
2.000000
0.07
NIH National Cancer Institute (NCI), United States of America (USA)
2.000000
0.07
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)
2.000000
0.07
Frederick National Laboratory for Cancer Research (FNLCR), United States of America (USA)
2.000000
0.07
City of Hope Comprehensive Cancer Center, United States of America (USA)
1.000000
0.03
UPMC Hillman Cancer Center (UPCI), United States of America (USA)
1.000000
0.03
Michigan Medicine, U-M, United States of America (USA)
1.000000
0.03
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
0.03
Washington University in St. Louis (WUSTL), United States of America (USA)
1.000000
0.03
Northwestern Memorial Hospital (NMH), NU, United States of America (USA)
1.000000
0.03
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA)
1.000000
0.03
Sylvester Comprehensive Cancer Center (Sylvester), UM, United States of America (USA)
1.000000
0.03
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)
1.000000
0.03
University of Massachusetts Chan Medical School (UMass Chan Medical School), United States of America (USA)
1.000000
0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
0.500000
0.02
Weill Cornell Medicine, United States of America (USA)
0.500000
0.02
Boston Children's Hospital (BCH), United States of America (USA)
0.333333
0.01
Harvard Medical School (HMS), United States of America (USA)
0.333333
0.01